Phase 2 Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas
概览
- 阶段
- 2 期
- 干预措施
- Magnetic Resonance Guidance
- 疾病 / 适应症
- Squamous Cell Carcinoma
- 发起方
- H. Lee Moffitt Cancer Center and Research Institute
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Improvement in Mean OAR Dose Reduction
- 状态
- 进行中（未招募）
- 最后更新
- 3个月前
概览
简要总结
The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma . The technique under study will be used to personalize the study treatment based on response, keeping all treatments within standard of care guidelines.
研究者
入排标准
入选标准
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •ECOG performance status of 0, 1
- •Patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck.
- •Patients with measurable disease, either at primary site or neck per RECIST 1.
- •For patients planned to receive chemotherapy, adequate hematologic, hepatic and renal function as outlined in protocol.
- •International normalized ratio of prothrombin time (INR) and prothrombin time (PT) within 28 days before randomization must be WNL for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history.
- •Negative serum pregnancy test within before starting study treatment in woman with childbearing potential.
排除标准
- •Pregnancy or lactation
- •Patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer.
- •Patients who had undergone definitive surgery for the index cancer.
- •Patients with distant metastatic disease
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
研究组 & 干预措施
Adaptive Radiotherapy treatment
Patients will undergo adaptive radiotherapy boost for head/neck squamous cell carcinomas. A base conventional IMRT plan of 46-50Gy in 2 Gy to gross disease in the primary/nodes and 41.4-45 Gy in 1.8 Gy to the elective nodes per fraction will be utilized. The MR simulation will be utilized for boost treatment planning. Patients will receive their 6th fraction of the week on the adaptive platform treating the gross disease until completion of the base plan to 20 Gy in 2Gy daily fractions (10 fractions). Each ART treatment will be recontoured/replanned by the treating head/neck radiation oncologist as deemed clinically or dosimetrically necessary.
干预措施: Magnetic Resonance Guidance
Adaptive Radiotherapy treatment
Patients will undergo adaptive radiotherapy boost for head/neck squamous cell carcinomas. A base conventional IMRT plan of 46-50Gy in 2 Gy to gross disease in the primary/nodes and 41.4-45 Gy in 1.8 Gy to the elective nodes per fraction will be utilized. The MR simulation will be utilized for boost treatment planning. Patients will receive their 6th fraction of the week on the adaptive platform treating the gross disease until completion of the base plan to 20 Gy in 2Gy daily fractions (10 fractions). Each ART treatment will be recontoured/replanned by the treating head/neck radiation oncologist as deemed clinically or dosimetrically necessary.
干预措施: Intensity-modulated radiotherapy
结局指标
主要结局
Improvement in Mean OAR Dose Reduction
时间窗: Up to 15 months
Feasibility of MR adaptive boost technique, as defined as achieving a reduction of mean OAR (parotids, submandibular glands, pharynx, oral cavity, tubarial glands, larynx, esophagus, and thyroid) doses greater than 7.5% compared to unadapted CT based plan. If 18 of 25 patients are meet the mean OAR criteria the approach will be considered feasible.
次要结局
- Percentage of patients achieving a complete metabolic response(Up to 15 months)
- Percentage of patients achieving a complete anatomic response(Up to 15 months)